Zevra Therapeutics (ZVRA, $8.64) was one of top quarterly gainers, jumping +2 to $8.64 per share. A.I.dvisor analyzed 844 stocks in the Biotechnology Industry over the last three months, and discovered that of them (6) charted an Uptrend while of them (3) trended down.